Stock Price & Analysis

Buy RVTY stock as it shows bullish momentum with a recent price increase and positive analyst sentiment. The stock has crossed above a critical moving average, indicating potential further upside.

Price Prediction for RVTY Stock in 2025

Based on current trends and analysis, RVTY stock is expected to reach $138-$140 by year-end 2025.
The stock is supported by positive analyst upgrades and strong earnings growth, with a potential upside driven by improved guidance and industry tailwinds.

The S1 support level for RVTY Stock is $107.97 ,The R1 resistant level for RVTY Stock is $118.5.

As of the end of day on 2025-03-17, the price of RVTY Stock was $111.71.

The target price for RVTY Stock according to analyst rating is 136.38, with the highest price target at 145.00 and the lowest at 120.00. Analysts have a Moderate Buy rating on RVTY Stock overall.

The market cap of RVTY is $13.4B.

RVTY is not overvalued based on current analysis. Here's the breakdown:

1. Analyst Targets: The average analyst target price is $138.24, indicating a 16.6% upside potential, suggesting analysts see significant growth ahead.

2. Financial Performance: RVTY reported a 5% revenue growth and improved EPS, though cautious guidance impacted investor sentiment, leading to a stock price drop.

3. Market Performance: The stock underperformed the broader market but outpaced its sector ETF, showing relative strength despite short-term setbacks.

4. Valuation Metrics: While specific metrics like P/E aren't provided, the stock's inclusion in an ETF with a 13.26% upside target supports its fair valuation.

5. Analyst Sentiment: A "Moderate Buy" rating with raised price targets from analysts like Barclays indicates confidence in RVTY's future.

In conclusion, RVTY appears fairly valued with growth potential, not overvalued.

Revvity, Inc. is a provider of health science solutions, technologies, and services, which delivers workflows from discovery to development, and diagnosis to cure. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The Life Sciences Segment applications include MicroBeta, The MuviCyte live-cell imaging system, The Signals Image Artist, The VICTOR Nivo multimode plate reader benchtop system, The EnSight multimode plate reader benchtop system, BioLegend LEGENDplex bead-based reagents, and The Quantum GX2 system. Its Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. It offers instruments, reagents, assay platforms and software to hospitals, and medical labs. It is focused on reproductive health, immunodiagnostics, and emerging market diagnostics.

RVTY stock is predicted to reach $140-$155 by 2030, driven by strong growth prospects and positive analyst sentiment. The stock could stabilize around $120 if market conditions deteriorate. Current price targets and fundamentals support this outlook.

RVTY has a total of 11500 employees.